Marker Therapeutics Q4 EPS $(0.09) Beats $(0.47) Estimate, Sales $1.103M Beat $723.000K Estimate

Marker Therapeutics (NASDAQ: MRKR) reported Q4 earnings with a loss of $(0.09) per share, surpassing the analyst estimate of $(0.47) by 81.68%. This represents a 79.29% increase in losses compared to $(0.42) per share in the same quarter last year. The company achieved sales of $1.103 million, exceeding the $723,000 estimate by 52.56%, although this reflects a 51.02% decrease from $2.252 million in the prior year.